Acoramidis Beneficial in Transthyretin Amyloid Cardiomyopathy

THURSDAY, Jan. 11, 2024 -- Acoramidis yields a significantly better four-step primary hierarchical outcome, including aspects of mortality and morbidity, than placebo for patients with transthyretin amyloid cardiomyopathy, according to a study...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news